C19H16BrNO2
Neat
370.25
Room Temperature
1161002-05-6; G15; (3aS, 4R, 9bR)-4-(6-bromo-1, 3-benzodioxol-5-yl)-3a, 4, 5, 9b-tetrahydro-3H-cyclopenta[c]quinoline; 3H-Cyclopenta[c]quinoline, 4-(6-bromo-1, 3-benzodioxol-5-yl)-3a, 4, 5, 9b-tetrahydro-, (3aS, 4R, 9bR)-; G-15; CHEMBL583543; (3AS, 4R, 9BR)-4-(6-BROMO-2H-1, 3-BENZODIOXOL-5-YL)-3H, 3AH, 4H, 5H, 9BH-CYCLOPENTA[C]QUINOLINE; (3aS, 4R, 9bR)-4-(6-bromobenzo[d][1, 3]dioxol-5-yl)-3a, 4, 5, 9b-tetrahydro-3H-cyclopenta[c]quinoline; 4-(6-Bromo-benzo[1, 3]dioxol-5-yl)-3a, 4, 5, 9b-tetrahydro-3H-cyclopenta[c]quinoline; (3aS*, 4R*, 9bR*)-4-(6-Bromo-1, 3-benzodioxol-5-yl)-3a, 4, 5 and 9b-3H-cyclopenta[c]quinoline; G15 Drug; 5DZD8Z9XMT; GRB-G15; GTPL3320; orb1299863; SCHEMBL24203417; cid_3136844; Compound G15-GPR30 antagonist; GLXC-10270; G15 (GRB-G15)
(3aS, 4R, 9bR)-4-(6-bromo-1, 3-benzodioxol-5-yl)-3a, 4, 5 and 9b-tetrahydro-3H-cyclopenta[c]quinoline
InChI=1S/C19H16BrNO2/c20-15-9-18-17(22-10-23-18)8-14(15)19-13-6-3-5-11(13)12-4-1-2-7-16(12)21-19/h1-5,7-9,11,13,19,21H,6,10H2/t11-,13-,19+/m0/s1